48,706
edits
(→Drugs) |
(→IHC) |
||
(One intermediate revision by the same user not shown) | |||
Line 36: | Line 36: | ||
<center> | <center> | ||
{| class="wikitable sortable" | {| class="wikitable sortable" | ||
!Clone | !Clone | ||
!IHC platform | |||
!Associated drug | !Associated drug | ||
!Testing required | !Testing required | ||
|- | |- | ||
| 28-8 | | 28-8 | ||
| Dako | |||
| Nivolumab<ref>{{Cite journal | last1 = Borghaei | first1 = H. | last2 = Paz-Ares | first2 = L. | last3 = Horn | first3 = L. | last4 = Spigel | first4 = DR. | last5 = Steins | first5 = M. | last6 = Ready | first6 = NE. | last7 = Chow | first7 = LQ. | last8 = Vokes | first8 = EE. | last9 = Felip | first9 = E. | title = Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. | journal = N Engl J Med | volume = 373 | issue = 17 | pages = 1627-39 | month = Oct | year = 2015 | doi = 10.1056/NEJMoa1507643 | PMID = 26412456 }}</ref> | | Nivolumab<ref>{{Cite journal | last1 = Borghaei | first1 = H. | last2 = Paz-Ares | first2 = L. | last3 = Horn | first3 = L. | last4 = Spigel | first4 = DR. | last5 = Steins | first5 = M. | last6 = Ready | first6 = NE. | last7 = Chow | first7 = LQ. | last8 = Vokes | first8 = EE. | last9 = Felip | first9 = E. | title = Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. | journal = N Engl J Med | volume = 373 | issue = 17 | pages = 1627-39 | month = Oct | year = 2015 | doi = 10.1056/NEJMoa1507643 | PMID = 26412456 }}</ref> | ||
| no testing for squamous carcinoma, pending further information for non-squamous | | no testing for squamous carcinoma, pending further information for non-squamous | ||
|- | |- | ||
| 22C3 | | 22C3 | ||
| Dako | |||
| Pembrolizumab<ref>{{Cite journal | last1 = Garon | first1 = EB. | last2 = Rizvi | first2 = NA. | last3 = Hui | first3 = R. | last4 = Leighl | first4 = N. | last5 = Balmanoukian | first5 = AS. | last6 = Eder | first6 = JP. | last7 = Patnaik | first7 = A. | last8 = Aggarwal | first8 = C. | last9 = Gubens | first9 = M. | title = Pembrolizumab for the treatment of non-small-cell lung cancer. | journal = N Engl J Med | volume = 372 | issue = 21 | pages = 2018-28 | month = May | year = 2015 | doi = 10.1056/NEJMoa1501824 | PMID = 25891174 }}</ref> | | Pembrolizumab<ref>{{Cite journal | last1 = Garon | first1 = EB. | last2 = Rizvi | first2 = NA. | last3 = Hui | first3 = R. | last4 = Leighl | first4 = N. | last5 = Balmanoukian | first5 = AS. | last6 = Eder | first6 = JP. | last7 = Patnaik | first7 = A. | last8 = Aggarwal | first8 = C. | last9 = Gubens | first9 = M. | title = Pembrolizumab for the treatment of non-small-cell lung cancer. | journal = N Engl J Med | volume = 372 | issue = 21 | pages = 2018-28 | month = May | year = 2015 | doi = 10.1056/NEJMoa1501824 | PMID = 25891174 }}</ref> | ||
| testing required | | testing required | ||
|- | |- | ||
| SP142 | | SP142 | ||
| Ventana | |||
| Atezolizumab<ref name=pmid26970723>{{Cite journal | last1 = Fehrenbacher | first1 = L. | last2 = Spira | first2 = A. | last3 = Ballinger | first3 = M. | last4 = Kowanetz | first4 = M. | last5 = Vansteenkiste | first5 = J. | last6 = Mazieres | first6 = J. | last7 = Park | first7 = K. | last8 = Smith | first8 = D. | last9 = Artal-Cortes | first9 = A. | title = Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. | journal = Lancet | volume = 387 | issue = 10030 | pages = 1837-46 | month = Apr | year = 2016 | doi = 10.1016/S0140-6736(16)00587-0 | PMID = 26970723 }}</ref> | | Atezolizumab<ref name=pmid26970723>{{Cite journal | last1 = Fehrenbacher | first1 = L. | last2 = Spira | first2 = A. | last3 = Ballinger | first3 = M. | last4 = Kowanetz | first4 = M. | last5 = Vansteenkiste | first5 = J. | last6 = Mazieres | first6 = J. | last7 = Park | first7 = K. | last8 = Smith | first8 = D. | last9 = Artal-Cortes | first9 = A. | title = Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. | journal = Lancet | volume = 387 | issue = 10030 | pages = 1837-46 | month = Apr | year = 2016 | doi = 10.1016/S0140-6736(16)00587-0 | PMID = 26970723 }}</ref> | ||
| testing required | | testing required | ||
|- | |- | ||
| SP263 | | SP263 | ||
| Ventana | |||
| Durvalumab | | Durvalumab | ||
| testing likely required | | testing likely required |
edits